Hau, Peter

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 7,405

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 1,052

Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology

Glioma Diagnosis and TreatmentOvarian cancer diagnosis and treatment

Cited by 433

Targeted tumor therapy with the TGF-β2 antisense compound AP 12009

SCHLINGENSIEPEN, K., SCHLINGENSIEPEN, R., STEINBRECHER, A., HAU, P., BOGDAHN, U., FISCHERBLASS, B., & JACHIMCZAK, P. (2006) · Cytokine & Growth Factor Reviews

TGF-β signaling in diseasesGlioma Diagnosis and Treatment

Cited by 195

O-09.03 Preliminary immunogenicity results from the dose escalation phase of a first-in-human study of the mRNA-based cancer vaccine CVGBM in patients with newly diagnosed MGMT-unmethylated glioblastoma

de Freitas Chama, L., Romer Roche, P., Tabatabai, G., Freres, P., Hau, P., Glas, M., Seidel, C., von Baumgarten, L., Burger, M., van den Bent, M., et al. (2025) · Oral Presentations

Glioma Diagnosis and TreatmentImmunotherapy and Immune Responses

Cited by 1